Tunicamycin inhibits diabetes.
Cell Physiol Biochem
; 29(3-4): 595-602, 2012.
Article
em En
| MEDLINE
| ID: mdl-22508066
ABSTRACT
BACKGROUND:
Autoimmune diseases are characterized by a breakdown of immunologic tolerance, and this breakdown can lead to life-threatening or lifelong disorders. Moreover; drugs that are used to treat these diseases are few in number and are associated with many serious adverse effects.METHODS:
We used the rat insulin promoter-glycoprotein mouse model to analyze the role of tunicamycin in the process of autoimmune diabetes; the P14 mouse model to analyze the effect of tunicamycin on CD8(+) T cells; chop knockout mice to analyze the role of tunicamycin on an endoplasmic reticulum stress model; and fluorescence-activated cell sorting, quantitative real-time polymerase chain reaction, and histologic methods.RESULTS:
We found that a single dose of tunicamycin reduced the activation and pancreatic infiltration of CD8(+) T cells. This activity delayed the incidence of virus-induced diabetes and improved survival rates.CONCLUSION:
Tunicamycin may offer therapeutic opportunities for T cell-mediated autoimmune diseases such as diabetes.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Tunicamicina
/
Linfócitos T CD8-Positivos
/
Diabetes Mellitus Experimental
/
Hipoglicemiantes
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
Cell Physiol Biochem
Assunto da revista:
BIOQUIMICA
/
FARMACOLOGIA
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
Alemanha